NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
Abstract The NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH was evaluated by questions related to hysterectomy, oophorectomy, and reported menstrual changes. Pre/perimenopausal women were asse...
Main Authors: | Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, Charles E. Geyer, Priya Rastogi, John P. Crown, Michael P. Thirlwell, David M. Ellison, Jean-Francois Boileau, Patrick J. Flynn, Jong-Hyeon Jeong, Eleftherios P. Mamounas, Norman Wolmark |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-05-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-021-00264-2 |
Similar Items
-
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
by: Pooja P. Advani, et al.
Published: (2023-05-01) -
Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
by: N. Lynn Henry, et al.
Published: (2022-11-01) -
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
by: Samuel A. Jacobs, et al.
Published: (2019-12-01) -
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
by: Samuel A. Jacobs, et al.
Published: (2020-01-01) -
SETTING OF PROSPECTIVE TRIALS: NSABP ORGANIZATION
by: Atilla Soran
Published: (2006-01-01)